Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1060

1.

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.

Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG.

J Natl Cancer Inst. 1995 May 17;87(10):751-6.

PMID:
7563153
[PubMed - indexed for MEDLINE]
2.

p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.

Berns EM, Klijn JG, van Putten WL, de Witte HH, Look MP, Meijer-van Gelder ME, Willman K, Portengen H, Benraad TJ, Foekens JA.

J Clin Oncol. 1998 Jan;16(1):121-7.

PMID:
9440732
[PubMed - indexed for MEDLINE]
3.

Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.

Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Jänicke F, Klijn JG.

J Clin Oncol. 1994 Aug;12(8):1648-58.

PMID:
8040677
[PubMed - indexed for MEDLINE]
4.

The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.

Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.

Cancer Res. 2000 Feb 1;60(3):636-43.

PMID:
10676647
[PubMed - indexed for MEDLINE]
Free Article
5.

High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.

Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M.

Cancer Res. 1993 Jun 1;53(11):2513-21.

PMID:
8388317
[PubMed - indexed for MEDLINE]
Free Article
6.

Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.

Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JG, Foekens JA.

Cancer Res. 2004 Jul 1;64(13):4563-8.

PMID:
15231667
[PubMed - indexed for MEDLINE]
Free Article
7.

The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.

Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot AJ, van Tienoven DT, Beex LV, Sweep FC.

Thromb Haemost. 2004 Mar;91(3):514-21.

PMID:
14983227
[PubMed - indexed for MEDLINE]
9.

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.

Cancer Res. 2002 Aug 15;62(16):4617-22.

PMID:
12183417
[PubMed - indexed for MEDLINE]
Free Article
10.

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Höfler H, Kiechle M, Schmitt M, Harbeck N.

J Clin Oncol. 2003 Mar 15;21(6):1022-8.

PMID:
12637466
[PubMed - indexed for MEDLINE]
11.

Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.

Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Foekens JA, Beex LV, Sweep CG.

Cancer Res. 2004 Jan 15;64(2):659-64.

PMID:
14744782
[PubMed - indexed for MEDLINE]
Free Article
12.

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA.

J Natl Cancer Inst. 2002 Jan 16;94(2):116-28.

PMID:
11792750
[PubMed - indexed for MEDLINE]
Free Article
13.

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M; German N0 Study Group.

J Natl Cancer Inst. 2001 Jun 20;93(12):913-20.

PMID:
11416112
[PubMed - indexed for MEDLINE]
Free Article
14.

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.

Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, et al.

J Clin Oncol. 1992 Aug;10(8):1284-91.

PMID:
1634918
[PubMed - indexed for MEDLINE]
15.

Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.

Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H.

Breast Cancer Res Treat. 1993;24(3):195-208.

PMID:
8435475
[PubMed - indexed for MEDLINE]
16.

Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.

Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.

J Pathol. 2001 Sep;195(2):236-43.

PMID:
11592104
[PubMed - indexed for MEDLINE]
17.

Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.

Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, Schildberg FW.

J Clin Oncol. 1995 Aug;13(8):2084-93.

PMID:
7636552
[PubMed - indexed for MEDLINE]
18.

Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.

Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV, Sweep FC.

Cancer. 2004 Aug 1;101(3):486-94.

PMID:
15274061
[PubMed - indexed for MEDLINE]
Free Article
19.

Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.

Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.

Clin Cancer Res. 1997 Feb;3(2):233-9.

PMID:
9815678
[PubMed - indexed for MEDLINE]
Free Article
20.

Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.

Grøndahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK, Brünner N.

Breast Cancer Res Treat. 1997 Apr;43(2):153-63.

PMID:
9131271
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk